Back

4D Flow CMR in the assessment of residual mitral regurgitation after TEER: correlation with left ventricular reverse remodelling using multiple CMR quantification methods

11 December 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Cardiovascular magnetic resonance in valvular heart disease Valvular Heart Disease EACVI Premium Access EACVI 2025 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Doctor Kamil Stankowski

Monzino Cardiology Centre, Milan (Italy)

6 More presentations in this session

Presentation thumbnail
Functional versus anatomical method for defining the LV base by CMR in Barlow's disease: what is the best approach for quantifying mitral regurgitation?
Doctor S. Leboube (Lausanne, CH)
Abstract Slides
Presentation thumbnail
Myocardial fibrosis on LGE MRI is associated with accelerated progression of aortic stenosis
Doctor K. Hirata (Kishiwada, JP)
Abstract Slides
Presentation thumbnail
Right ventricular-pulmonary arterial coupling in patients with tricuspid regurgitation: a new cardiac magnetic resonance quantification method
Doctor D. Escribano Garcia (Barcelona, ES)
Abstract Slides
Presentation thumbnail
The impact of aortic distensibility in patients with bicuspid aortic valve stenosis
Doctor D. Da Silva Correia (Lisbon, PT) Doctor J. Abecasis (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Left atrioventricular coupling in pediatric patients with isolated mitral valve prolapse, preserved ejection fraction and moderate degree of mitral regurgitation.
Doctor F. Shokeir (Mansoura, EG)
Abstract Slides

Access the full session

Session thumbnail
Cardiovascular magnetic resonance in valvular heart disease

The Event

Event poster

EACVI 2025

11 December - 13 December 2025
You may be interested in
thumbnail
Congress Presentation
When to use cardiac magnetic resonance in aortic stenosis
thumbnail
Congress Presentation
Dealing with technical and patient-related challenges in CMR: tips and tricks - discussion
thumbnail
Congress Presentation
Strategies for atrioventricular valve disease assessment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources